ArticleFrontiers in cellular and infection microbiology2026
Probiotic supplementation as a nutritional strategy for the prevention and management of sarcopenia in older adults.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenia, defined as the loss of skeletal muscle mass, strength, and functional capacity over time, poses a significant health burden among older adults. A growing body of evidence indicates that the gut microbiota contributes to inflammation and metabolic regulation, mitochondrial function, and anabolic signaling, thereby shaping the gut-muscle axis. Probiotic supplementation has gained traction as a nutritional approach for the regulation of microbiome-derived metabolites. The present study aims to assess the rationale for probiotic supplementation to prevent and manage sarcopenia in older individuals. Methods: Using data from NHANES (2011-2018; n = 3,500), UK Biobank (n = 5,000), and GMrepo (n = 800), we examined associations between probiotic exposure and muscle outcomes, inflammation, and microbiome diversity. C2C12 myotubes were used in vitro under probiotic-conditioned media (PCM). The interactions of short-chain fatty acids (SCFAs) with the regulatory proteins (mTOR, AMPK, NF-κB) were evaluated using molecular docking simulations. Random Forest and XGBoost models were used to predict sarcopenia risk using integrated multimodal features, with a 70% training and 30% validation split. Results: Probiotic users exhibited greater handgrip strength (UK Biobank: 27.2 ± 4.8 kg vs. 25.1 ± 5.2 kg), higher fat-free mass (57.4 ± 10.6 kg vs. 56.2 ± 11.0 kg), and lower inflammatory burden compared to non-users. PCM increased fusion index (85.6 ± 2.3% vs. 78.9 ± 3.2%, p < 0.01), myotube diameter (45.2 ± 6.3 μm vs. 40.1 ± 5.7 μm, p < 0.05), and MyoD (2.1-fold), Myogenin (1.8-fold), and MyHC (2.2-fold). NF-κB and TNF-α were decreased (~0.60-fold and 0.65-fold, respectively), and PGC-1α was increased (1.9-fold). Butyrate docking revealed high binding affinity for AMPK (-6.9 kcal/mol), mTOR (-6.4 kcal/mol), and NF-κB (-6.0 kcal/mol). The performance metrics achieved highly in XGBoost with 88% accuracy. Discussion: This comprehensive framework positions probiotics as a precision nutrition intervention for sarcopenia prevention, targeting muscle-sparing effects through microbiome modulation that stimulates coordinated immunometabolic and anabolic actions, with AI-enhanced, individualized risk prediction for healthy aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.